GeNeuro Gets European Patent for ALS Drug Candidate GNK-301

GeNeuro, an NRx Pharmaceuticals subsidiary, has been awarded European patent rights for GNK-301, a drug candidate to treat Amyotrophic Lateral Sclerosis (ALS). The invention is based on the discovery that ALS may be caused by reactivation of the Human Endogenous Retrovirus K (HERV K) Envelope protein. GNK-301 has shown to prevent neurotoxic effects of K Env in nonclinical subjects and human motor neuron cells. GeNeuro plans to initiate human Phase I trials in the US and Europe in H2 2027.